By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



8 rue de la Croix Jarry

Paris    75013  France
Phone: 33-0-1-81-69-16-00 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Cellectis
Symbol: CLLS



Company News
Patient Dies in Cellectis (CLLS)' Groundbreaking CAR-T Trial, Forcing a Halt to Trials 9/5/2017 5:34:32 AM
Cellectis (CLLS)’ UCART123 Administered To First Patient With BPDCN In Phase I Clinical Trial At MD Anderson Cancer Center 8/18/2017 7:17:57 AM
Cellectis (CLLS) Reports Financial Results For 2nd Quarter And First Six Months 2017 8/3/2017 7:54:24 AM
Cellectis (CLLS): Calyxt Announces Pricing of $56 Million Initial Public Offering 7/20/2017 9:16:10 AM
Cellectis (CLLS)' Calyxt Sets Terms For $100 Million IPO 7/10/2017 6:20:46 AM
Cellectis (CLLS) Appoints Rainer Boehm, M.D. And Hervé Hoppenot To Board Of Directors 6/29/2017 6:38:16 AM
First In Human Administration Of UCART123 In Cellectis (CLLS)’ AML Phase I Clinical Trial At Weill Cornell Medicine, Newyork-Presbyterian Hospital 6/28/2017 6:57:05 AM
Cellectis (CLLS) Reports Results From Annual General Meeting Held On June 26, 2017 6/27/2017 7:05:48 AM
Cellectis (CLLS): Annual General Meeting Of June 26, 2017 6/12/2017 8:41:57 AM
Cellectis (CLLS) Patent Encompassing Broad Uses Of Gene Editing Technologies Maintained By USPTO 5/11/2017 7:28:35 AM